CDNA CAREDX INC

CareDx Launches AiTraC Conference

CareDx Launches AiTraC Conference

CareDx’s transplant specific algorithms enable personalized care

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today the launch of AiTraC 2020, the inaugural meeting on AI solutions for transplantation that will be held March 27-28, 2020 in South San Francisco, CA.

CareDx, the Paris Transplant Group, and Cibiltech are cohosting AiTraC 2020. This meeting will bring together healthcare professionals and AI technology experts to discuss how data solutions can improve transplant patient outcomes. Confirmed speakers include Nobel Laureate Alvin Roth, Duke Chair of Surgery Allan Kirk, and ex-CTO of WebMD and double lung transplant recipient David Guthrie.

“At CareDx, we believe that improving long term outcomes for transplant patients will come from synthesizing complex and disparate data to create personalized decision support tools. AiTraC 2020 is a first step to moving the field in this direction,” said Sasha King, Chief Marketing Officer at CareDx. “The Paris Transplant Group and Cibiltech are incredible, like-minded partners with a focus on how augmented intelligence can best impact transplant patient care.”

“I often say that AI will not replace clinicians, but the clinicians who use AI solutions will replace the clinicians who do not. This is a first meeting to discuss how we can best use AI to support the care for patients. And by AI, I mean augmented as well as artificial intelligence,” said Alexandre Loupy, MD, Professor at the Paris Transplant Group. “Tools using machine learning for transplant care are now a reality, and the community will come together to discuss how to best implement these solutions and shape the future of care.”

For more information about AiTraC 2020 and details on registration, visit -conference.com/

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: .

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

Investor Relations

Greg Chodaczek

646-924-1769

 

EN
04/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch